Core Viewpoint - The stock price of Diya Co., Ltd. (301177.SZ) has declined significantly, closing at 32.30 yuan with a drop of 7.45%, currently in a state of underperformance [1] Group 1: Company Overview - Diya Co., Ltd. was listed on the Shenzhen Stock Exchange's ChiNext board on December 15, 2021, issuing 40.01 million new shares at a price of 116.88 yuan per share [1] - The company reached a peak stock price of 180 yuan on its first trading day, followed by a continuous decline in stock price [1] Group 2: Financial Details - The total amount raised from the initial public offering (IPO) was 4.676 billion yuan, with a net amount of 4.444 billion yuan after deducting issuance costs, exceeding the originally planned net fundraising amount by 3.16 billion yuan [1] - The initial prospectus indicated that Diya Co., Ltd. originally planned to raise 1.284 billion yuan for various projects, including channel network construction, information system development, diamond jewelry R&D, and working capital supplementation [1] - The total issuance costs for the IPO amounted to 233 million yuan, with underwriting and sponsorship fees accounting for 217 million yuan [1]

Group 1 - The stock price of Wanrun New Energy (688275.SH) fell by 5.02% to close at 73.10 yuan [1] - Wanrun New Energy was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 29, 2022, with an initial public offering (IPO) of 21,303,795 shares at a price of 299.88 yuan per share [1] - The stock reached an all-time high of 259.99 yuan on its first trading day but is currently in a state of decline [1] Group 2 - The total funds raised from the IPO amounted to 638.86 million yuan, with a net amount of 614.56 million yuan after deducting issuance costs, exceeding the original plan by 4.88 billion yuan [1] - The funds are intended for projects including high-performance lithium-ion battery materials and a research center for lithium battery cathode materials [1] - The issuance costs for the IPO were 24.30 million yuan, with underwriting fees accounting for 21.20 million yuan [1] Group 3 - On May 24, 2023, Wanrun New Energy announced a profit distribution plan, distributing a cash dividend of 3.52 yuan per share and a capital increase of 0.48 shares per share [2] - The total cash dividend distributed amounted to approximately 299.96 million yuan, with a capital increase of 40,903,285 shares, resulting in a new total share capital of 126,118,463 shares [2] - The record date for the equity distribution was set for May 30, 2023, with the ex-dividend date on May 31, 2023 [2]

Core Viewpoint - Aojie Technology (688220.SH) has experienced a significant decline in stock price, closing at 81.67 yuan with a drop of 7.92%, currently in a state of underperformance [1] Group 1: Company Overview - Aojie Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 14, 2022, with an initial stock issuance of 41.83 million shares at a price of 164.54 yuan per share [1] - The company raised a total of 6.883 billion yuan through its initial public offering (IPO), with a net amount of 6.546 billion yuan after deducting issuance costs, exceeding the original plan by 4.166 billion yuan [2] Group 2: Fund Utilization - The funds raised are intended for various projects, including the design of new communication chips, smart IPC chip design, integration of multiple wireless protocols, high-precision navigation solutions, research center construction, and working capital supplementation [2] Group 3: Financial Details - The total issuance costs for Aojie Technology's IPO amounted to 337 million yuan, with underwriting and sponsorship fees accounting for 310 million yuan [3]

Core Viewpoint - Shan Shui Technology (301190.SZ) has experienced a significant decline in stock price, closing at 22.81 yuan with a drop of 9.12% on February 2 [1] Group 1: Company Overview - Shan Shui Technology was listed on the Shenzhen Stock Exchange's ChiNext board on December 24, 2021, with a total of 53.66 million shares issued, accounting for 25% of the total share capital post-issuance [1] - The initial offering price was set at 27.85 yuan per share, with the stock reaching a peak of 44.00 yuan on its first trading day, which remains the highest price to date [1] Group 2: Fundraising and Financials - The total amount raised from the issuance was 1.494 billion yuan, with a net amount of 1.384 billion yuan after deducting issuance costs, exceeding the original plan by 70.92 million yuan [1] - The company aimed to raise 1.313 billion yuan for projects including the construction of a facility for producing 61,000 tons of chloropyridine and 15,000 tons of 2-chloro-5-chloromethylpyridine, as well as a research and development building [1] Group 3: Underwriting and Fees - The lead underwriter for the issuance was Zhongyuan Securities Co., Ltd., with the responsible representatives being Wang Xianfu and Zhao Yimeng [1] - The total issuance costs amounted to 110 million yuan, with Zhongyuan Securities receiving underwriting and sponsorship fees of 94.8964 million yuan [1]

Group 1 - The company, Paike New Materials (605123.SH), has announced a plan to issue convertible bonds to raise up to RMB 158 million, which will be used for high-end energy equipment manufacturing projects, a technology research institute project, and to supplement working capital [1] - The convertible bonds will be issued at a face value of RMB 100 each and will have a term of six years from the date of issuance [1] - The interest rate for the convertible bonds will be determined by the company's board of directors in consultation with the underwriters based on market conditions and company specifics [1] Group 2 - The issuance of the convertible bonds will be authorized by the company's shareholders and will target various investors, including individuals and institutions with accounts at the Shanghai branch of China Securities Depository and Clearing Corporation [2] - Paike New Materials was listed on the Shanghai Stock Exchange on August 25, 2020, with an initial public offering of 27 million shares at a price of RMB 30.33 per share, raising a total of RMB 819 million [2] - The company previously raised RMB 1.6 billion through a private placement of shares, with net proceeds of approximately RMB 1.58 billion after deducting issuance costs [3] Group 3 - The total amount raised by Paike New Materials from the two fundraising efforts is approximately RMB 2.42 billion [4]

Core Viewpoint - The stock price of Tom Cat (300459.SZ) closed at 4.90 yuan, reflecting a decline of 4.11% [1] Group 1: Stock Performance - On May 4, 2023, Tom Cat reached a nearly 8-year high of 9.47 yuan during intraday trading [2] - The recent closing price indicates a significant drop from its peak earlier in the year [1][2] Group 2: Analyst Coverage - Guosen Securities analyst Zhang Heng initiated coverage on Tom Cat on May 4, 2023, with a "Buy" rating, highlighting the company's advantages in AIGC scenario implementation [2]

Group 1 - The stock of Zhongchumai (688267.SH) closed at 28.92 yuan, experiencing a decline of 10.02%, indicating it is currently in a broken state [1] - Zhongchumai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 16, 2022, with an initial offering price of 41.90 yuan per share [1] - The total amount raised by Zhongchumai during its IPO was 1.846 billion yuan, with a net amount of 1.691 billion yuan after deducting issuance costs, which was 907 million yuan more than the original plan [1] Group 2 - The company planned to raise 784 million yuan for projects related to "environmental new materials and intermediates" and "industrialization of special molecular sieves, environmental catalysts, and automotive exhaust purification catalysts" [1] - The total issuance costs for Zhongchumai's public offering amounted to 155 million yuan, with the lead underwriter, Shenwan Hongyuan Securities, receiving 132 million yuan in underwriting fees [1] - Shenwan Innovation Investment, a subsidiary of the underwriter's parent company, participated in the strategic placement of the IPO, acquiring approximately 3.25% of the public offering, which equates to 1.43198 million shares, with an investment amount of approximately 59.999962 million yuan [2]

Core Viewpoint - The announcement reveals that the controlling shareholder, Asia-Pacific Electromechanical Group Co., Ltd., has reduced its stake in Asia-Pacific Shares, indicating a significant change in ownership structure and potential implications for investor sentiment [1] Group 1: Shareholding Changes - Asia-Pacific Group reduced its holdings by 7,364,100 shares from January 20 to January 30, 2026, representing 0.9964% of the total share capital of the listed company [1] - The average selling price during this reduction was 17.33 yuan per share, resulting in a total cash inflow of approximately 127.62 million yuan [1] - Post-reduction, Asia-Pacific Group holds 269,128,417 shares, decreasing its ownership percentage from 37.41% to 36.41% [1] Group 2: Cumulative Reductions - Since the first reduction on November 24, 2022, Asia-Pacific Group has cumulatively reduced its stake by 13,000,700 shares, realizing approximately 10.3 million yuan in cash [1] - The total shares held by Asia-Pacific Group and its concerted parties decreased from 44% to 43% after the recent reduction [1]

根据森霸传感披露的2024年年度报告，该公司不存在控股股东，实际控制人为单森林。单森林与单颖系 父女关系。 森霸传感于2026年1月7日发布关于实际控制人之一致行动人减持计划实施完毕暨一致行动关系解除的公 告。上海通怡投资管理有限公司-通怡康腾8号私募证券投资基金金(以下简称"康腾8号")于2025年11月28 日至2026年1月5日期间，通过集中竞价交易(含盘后定价)、大宗交易合计减持森霸传感3,086,930股股 份，减持比例1.0918%。经计算，康腾8号本次减持金额约为3,760.86万元至4,230.20万元。康腾8号曾于 2021年12月13日与单森林、单颖签订《一致行动人协议》(以下简称《一致行动人协议》)，约定一致行 动协议有效期限为自一致行动协议签署之日起至康腾8号不再持有森霸传感股权为止。康腾8号本次减持 森霸传感股份后，不再持有森霸传感股份，按照《一致行动人协议》的约定，不再是森霸传感实际控制 人的一致行动人。 据新浪财经，通怡康腾8号私募证券投资基金最初持股69.8万股，占总股本的0.39%。通怡康腾8号私募 证券投资基金从2025年2月20日起，第一次减持森霸传感股份，迄今为止，累计 ...

经上海证券交易所科创板股票上市委员会2019年7月30日审核同意，并经中国证券监督管理委员会2019 年9月20日下发《关于同意青岛海尔生物医疗股份有限公司首次公开发行股票注册的批复》（证监许可 [2019]1742号）核准，同意海尔生物公开发行人民币普通股不超过79,267,940股，每股发行价格为人民 币15.53元，募集资金总额为人民币1,231,031,108.20元，实际到账金额人民币1,161,576,074.14元，包括 尚未划转的其他发行费用。上述募集资金于2019年10月22日到位，并经安永华明会计师事务所（特殊普 通合伙）审验并出具了安永华明（2019）验字第61433766_J04号验资报告。主承销商为国泰君安证券股 份有限公司司（现名"国泰海通证券股份有限公司"）。 (责任编辑：马欣) 中国经济网北京2月2日讯 海尔生物(688139.SH)近日发布公告称，公司近日收到青岛海创睿股权投资基 金中心（有限合伙）（以下简称"海创睿"）出具的《关于股份减持计划的告知函》。因自身资金需求， 海创睿拟通过集中竞价方式减持海尔生物股份，减持股份占海尔生物总股本的比例不超过0.85%，即不 超过2, ...